New 3D Printed Medicines for Children with Toxoplasmosis
Pediatric toxoplasmosis: Addressing unmet medical need with 3D printed dose flexible delivery systems of pyrimethamine, sulphadiazine and leucovorin
['FUNDING_R01'] · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · NIH-11191388
This project aims to create new, easy-to-dose medicines using 3D printing for children suffering from toxoplasmosis.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR (nih funded) |
| Locations | 1 site (COLLEGE STATION, UNITED STATES) |
| Trial ID | NIH-11191388 on ClinicalTrials.gov |
What this research studies
Children with toxoplasmosis currently face challenges because there are no specific pediatric versions of their necessary medications, pyrimethamine and sulfadiazine. This means pharmacists often have to mix these drugs by hand, which can lead to concerns about whether the dose is accurate or consistent. Our project is developing a new way to make these medicines using 3D printing technology. This method would allow doctors to create exact, flexible doses right in the hospital, ensuring children receive the precise amount of medication they need.
Who could benefit from this research
Good fit: This work is primarily for pediatric patients, especially infants and young children, who need treatment for congenital or acquired toxoplasmosis.
Not a fit: Patients who do not have toxoplasmosis or are adults may not directly benefit from these specific pediatric formulations.
Why it matters
Potential benefit: If successful, this work could provide safer, more accurate, and more accessible medication options for children with toxoplasmosis.
How similar studies have performed: While 3D printing for drug delivery is an emerging field, this specific application to address the unmet needs for pediatric toxoplasmosis formulations is novel.
Where this research is happening
COLLEGE STATION, UNITED STATES
- TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR — COLLEGE STATION, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KHAN, MANSOOR A — TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR
- Study coordinator: KHAN, MANSOOR A
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.